Attachment
Recently announced PWRM has new research and unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood. These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
NuroPro® was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these new results, NuroPro® now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
About Power3 Medical Products
Power3 Medical Products, Inc. (PWRM.OB) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, currently engaged in Phase II clinical trials. These products are designed to analyze proteins and their mutations to assess an individual’s risk for developing disease later in life, a patient’s likelihood of responding to a particular drug, a patient’s risk of disease progression and disease recurrence, to measure a patient’s exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity.
For more information, please visit http://www.power3medical.com.
Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN)
About Bio-Matrix Scientific Group
Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN)
For more information visit : http://bmsn.com
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism (EULAR) on Saturday, June 19.
About Human Genome Sciences
The mission of HGSI is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. HGS, Human Genome Sciences and BENLYSTA are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners. For more information about HGS, please visit the Company’s web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to medinfo@hgsi.com or by calling HGS at (877) 822-8472.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer
: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.DoubleInStocks publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
DoubleInStocks would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com
** The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.
Photo:
http://www.prlog.org/
